Sociedad Americana de Hirudoterapia

The Effects of Dextran on Postoperative Thrombosis and Hemodilution in Microvascular Head and Neck Reconstruction.

Research article published in Annals of plastic surgery (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportEnsayos clínicosDesarrollo de fármacosFilipan et al. · Annals of plastic surgery, 2020

Abstract

BACKGROUND: Free tissue transfer is an integral part of reconstructive head and neck surgery today. Although increased experience and refinements in techniques have minimized flap loss, pharmacological agents have been used to prevent thrombus formation and flap failures, despite their questionable effectiveness. The aim of this study is to investigate the use of dextran 40 in thrombosis prophylaxis, as well as its effects on blood coagulability and flap survival. METHODS: This is a retrospective analysis of 176 free flaps performed at University Hospital Dubrava, Zagreb, Croatia, during a 4-year period. A comparison was made between 2 patient groups, based on their respective postoperative prophylaxis protocols. All patients were treated with low-molecular-weight heparin as deep vein thrombosis prevention, until patient mobilization. Group 1 was on dextran 40 protocol, whereas group 2 did not receive additional treatment. Primary outcome of the study was determined as flap loss rate, whereas secondary outcome was evaluated as the rate of thrombosis or hemorrhage. The hemodilution potential of dextran 40 was examined through blood count laboratory values. RESULTS: Total flap survival rate was 90.34%. There were 16 free flap losses and 1 partial loss overall. Anastomoses were re-explored in a total of 27 cases, of which 17 were salvaged. There were 29 events of hemorrhage or arterial or venous thrombosis: 17 in group 1 and 12 in group 2. A sum of 26 incidences of other postoperative complications was recorded, 13 in each group. Hemodilution status showed a statistically significant reduction in erythrocyte count and hemoglobin and hematocrit levels in the group receiving dextran 40, on postoperative days 1 and 3, but no such effect was observed on postoperative platelet count. CONCLUSIONS: Although dextran 40 has been shown to have a valuable effect on hemodilution, which is beneficial in microsurgery, it did not demonstrate better outcomes in terms of flap survival. Because it can cause serious systemic complications, it is better not to administer it routinely. However, its important influence on reduction in erythrocyte count and hemoglobin and hematocrit levels should be further investigated.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansCroatiaDextransFree Tissue FlapsHead and Neck NeoplasmsHemodilutionMicrosurgeryPlastic Surgery ProceduresPostoperative ComplicationsRetrospective StudiesThrombosisTreatment Outcome

Resumen

Free tissue transfer is an integral part of reconstructive head and neck surgery today. Although increased experience and refinements in techniques have minimized flap loss, pharmacological agents have been used to prevent thrombus formation and flap failures, despite their questionable effectiveness.

Por qué esto importa para la hirudoterapia

Este estudio retrospectivo investiga el uso de dextrano 40 para la profilaxis de la trombosis postoperatoria y sus efectos hemodilucionales en 176 casos de reconstrucción microvascular de cabeza y cuello. Los hallazgos indican que, si bien el dextrano 40 redujo significativamente los niveles de eritrocitos y hemoglobina, no mejoró las tasas de supervivencia del colgajo en comparación con el grupo control y planteó riesgos de complicaciones sistémicas graves. Esta investigación es altamente relevante en cuanto a contexto para la ASH porque la reconstrucción microvascular de cabeza y cuello es un entorno quirúrgico primario en el que se utilizan sanguijuelas medicinales para rescatar colgajos en riesgo de falla debido a la congestión venosa. Destaca los desafíos clínicos continuos para encontrar una anticoagulación segura y eficaz en este mismo ámbito quirúrgico. Sin embargo, el estudio en sí no tiene una participación directa con las sanguijuelas ni con la hirudoterapia.

Citación

The Effects of Dextran on Postoperative Thrombosis and Hemodilution in Microvascular Head and Neck Reconstruction.

Filipan et al. · Annals of plastic surgery, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.